NEW YORK (GenomeWeb News) – Medical diagnostic company Myconostica said yesterday that it has received a license from Health Canada to sell its Aspergillus molecular diagnostic test in Canada.

Myconostica's MycAssay Aspergillus detects Aspergillus DNA in lower respiratory tract samples. Results of the test aid physicians in diagnosing immunocompromised patients suspected of having an infection caused by the fungus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.